PharmAbcine, biotech company focusing on the development of antibody therapeutics, has signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigational olinvacimab (TTAC-0001), PharmAbcine’s leading antibody therapeutics pipeline in oncology.
 
Under the agreement, Binex is responsible for large-scale manufacturing of clinical investigational material for PharmAbcine for its global Phase 2 trials on olinvacimab + immunotherapy combination for metastatic triple negative breast cancer (the U.S. included) and trials on various common solid tumors. Binex has been a clinical manufacturing partner of PharmAbcine since early global clinical trials on olinvacimab.
 
“Contract manufacturing organization agreement with Binex enables us to secure the steady supply of investigational material for multinational clinical trials and trials on various common solid tumors,” said Jin-san Yoo, chief executive officer, PharmAbcine. “We will remain fully committed to the swift development of olinvacimab in use for treatment of recurrent glioblastoma multiforme (rGBM) and metastatic triple negative breast cancer (mTNBC).”
 
Olinvacimab, an anti-vascular endothelial growth factor receptor 2 (VEGFR2), targets and inhibits tumor angiogenesis-inducing VEGFR2. PharmAbcine is conducting a Phase 2 clinical trial on olinvacimab in patients with Avastin-refractory rGBM in the U.S. and Australia. In addition, Phase 1b trials on olinvacimab plus PD-1 antibody Keytruda (pembrolizumab) combination for rGBM and mTNBC are still going on in Australia in collaboration with MSD (Merck).